{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Drug-Related Deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"}]}],"title":"Drug-Related SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}],"title":"Drug-Related AEs Leading to Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"}]}],"title":"Grade 3/4 AEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade 3 = Severe; Grade 4 = Life-threatening or disabling.","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG004","title":"Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG005","title":"Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG006","title":"Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG007","title":"Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"From the date of first dose until at least 30 days after the last dose of study drug (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])","title":"Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0.","type":"SECONDARY","unitOfMeasure":"participants"}